Dr Lal Path Labs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?

Listen to this article in summarized format

Dr Lal Path Labs shares jumped to a fresh 52-week high of Rs 1,895 apiece on Monday, rising more than 12% in just two sessions. The stock is on track to record its sharpest single-day surge since early May this year.

The company on Friday reported a 28% year-on-year (YoY) increase in consolidated net profit to Rs 169.5 crore for the April-June quarter of FY27, from Rs 132.4 crore in the corresponding quarter of the previous financial year. The firm’s revenue from operations, meanwhile, rose over 19% YoY to Rs 797.7 crore during the quarter under review.

Along with the Q1 results, Dr Lal Path Labs announced an interim dividend of Rs 5 per equity share for the ongoing financial year 2027, with July 30 fixed as the record date to determine the eligibility of shareholders to receive the payout.

Dr Lal PathLabs posts higher first-quarter profit on healthy demand for tests

Also read |

Nomura on Dr Lal Path Labs share price

Nomura maintained its ‘Buy’ call on the shares of Dr Lal Path Labs but increased its target price to Rs 2,085 apiece from Rs 1,860 apiece. The latest target price implies an upside potential of 18.5% from the stock’s previous closing price of Rs 1,759.20 apiece.

Nuvama on Dr Lal Path Labs share price

Nuvama also noted that Dr Lal Path Labs beat earnings estimates. It said the company remains on a robust growth path owing to network expansion, 12–15 labs and 2–4 radiology centres in FY27, CGHS and ECHS price hike-led growth, sustained traction in the Delhi NCR market, double-digit growth, and a strong Suburban turnaround, along with a robust balance sheet which could unlock inorganic optionality.The brokerage raised its earnings estimates for FY27 and FY28. It maintained its ‘Buy’ rating on the stock while increasing its target price to Rs 2,140 apiece. This implies an upside potential of nearly 22%.

JM Financial on Dr Lal Path Labs share price

JM Financial said Dr Lal delivered a strong Q1FY27, beating estimates by a substantial margin and delivering a second consecutive quarter of 15%+ growth. “We remain positive on Dr Lal, supported by its market leadership, structurally superior B2C mix, healthy cash generation and revival of structural growth in the industry,” it said.The domestic brokerage maintained its ‘Buy’ call on Dr Lal Path Labs shares but increased its target price to Rs 2,195 apiece, implying nearly 25% upside.

Why is market rising today? Sensex soars 600 points, Nifty above 23,900. 6 key factors driving the rally